Weekly administration of paclitaxel attenuated rectal stenosis caused by multiple peritoneal recurrence 8 years after the resection of gastric carcinoma

Gastric Cancer

Volumn 6, Issue 4, 2003, Pages 243-249

  Sakurai, Yoichi ^a   Yoshida, Ikuo ^a   Tonomura, Shuhei ^a   Sakai, Wakana ^a   Nakamura, Yasuko ^a   Imazu, Hiroki ^a   Matsubara, Toshiki ^a   Ochiai, Masahiro ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Gastric carcinoma; Peritoneal dissemination; Rectal stenosis; Weekly paclitaxel

Indexed keywords

BARIUM; FLUOROPYRIMIDINE; PACLITAXEL;

ABDOMINAL PAIN; ADVANCED CANCER; AGED; ARTICLE; BARIUM ENEMA; CANCER RECURRENCE; CASE REPORT; CLINICAL TRIAL; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIARRHEA; DRUG DOSE REGIMEN; FEMALE; FIBERSCOPE ENDOSCOPY; HUMAN; IMAGE ANALYSIS; LYMPH NODE METASTASIS; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERITONEUM METASTASIS; PRIORITY JOURNAL; QUALITY OF LIFE; RECTUM STENOSIS; RECTUM TUMOR; ROUX Y ANASTOMOSIS; STOMACH CARCINOMA; TOTAL STOMACH RESECTION;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA; CONSTRICTION, PATHOLOGIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTRECTOMY; HUMANS; PACLITAXEL; PERITONEAL NEOPLASMS; RECTAL DISEASES; RECURRENCE; STOMACH NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0942266077     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-003-0250-7     Document Type: Article

References (44)

1. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2003;87:236-42.
2. Wils J. The treatment of advanced gastric cancer. Semin Oncol 1996;23:397-406.
3. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, 2nd English ed. Gastric Cancer 1998;1:10-24.
4. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987;47:2486-93.
5. Shiraishi N, Inomata M, Osawa N, Yasuda K, Adachi Y, Kitano S. Early and late recurrence after gastrectomy for gastric carcinoma. Univariate and multivariate analyses. Cancer 2003;89:255-61.
6. Adachi Y, Oshiro T, Mori M, Maehara Y, Sugimachi K. Prediction of early and late recurrence after curative resection for gastric carcinoma. Cancer 1996;77:2445-8.
7. Iwanaga T, Koyama H, Furukawa H, Taniguchi H, Wada A, Tateishi R. Mechanisms of late recurrence after radical surgery for gastric carcinoma. Am J Surg 1978;135:637-40.
8. Health and Welfare Statistics Association. The movement of population. Tokyo: Health and Welfare Statistics Association; 1999.
9. Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med 1995; 333:32-41.
10. Maehara Y, Moriguchi S, Kakeji Y, Kohnoe S, Korenaga D, Haraguchi M, et al. Pertinent risk factors and gastric carcinoma with synchronous peritoneal dissemination or liver metastasis. Surgery 1991;110:820-3.
11. Balthazar EJ, Rosenberg HD, Davidian MM. Primary and metastatic scirrrhous carcinoma of the rectum. AJR Am J Roentgenol 1979;132:711-5.
12. Ishikawa T, Jyono S, Mizuguchi Y, Ushio K, Yamada T, Yoshida S, et al. Morphological diagnosis of metastatic colon carcinoma: analysis of radiological findings. I to Cho 1988;23:617-30.
13. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-7.
14. Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet 1994;344:1267-72.
15. Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol 1994;5 (Suppl 6):S3-S6.
16. Lanni JS, Lowe SW, Licitra EJ, Liu JO, Jacks T. p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc Natl Acad Sci U S A 1997;94:9679-83.
17. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325-7.
18. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990; 82:1247-59.
19. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83:1797-805.
20. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Int Med 1989;111:273-9.
21. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993;85:384-8.
22. O'Boyle KP, Wang Y, Schwartz EL, Regl DL, Einzig A, Dutcher JP, et al. Development of two radioimmunoassays to detect paclitaxel in sera and in cerebrospinal, ascitic, and pleural fluids. Cancer 1997;79:1022-30.
23. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF. Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 1998;4:269-74.
24. Cascinu S, Graziano F, Cardarelli N, Marcellini M, Giordani P, Menichetti ET, et al. Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs 1998;9:307-10.
25. Garcia AA, Leichman CG, Lenz HJ, Baranda J, Lujan R, Casagrande Y, et al. Phase II trial of outpatient schedule of paclitaxel in patients with previously untreated metastatic, measurable adenocarcinoma of the stomach. Jpn J Clin Oncol 2003;31:275-78.
26. Murad AM, Petroianu A, Guimaraes RC, Aragao BC, Cabral LO, Scalabrini-Neto AO. Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen. Am J Clin Oncol 1999;22:580-6.
27. Kim YH, Shin SW, Kim BS, Kim JH, Kim JG, Mok YJ, et al. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 1999;85:295-301.
28. Kollmannsberger C, Quietzsch D, Haag C, Lingenfelser T, Schroeder M, Hartmann JT, et al. A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 2003;83:458-62.
29. Seidman AD, Hudis CA, Albanel J, Tong W, Tepler I, Currie V, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998;16:3353-61.
30. Eisenhauer EA. Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998. Ann Oncol 1998;9:1047-52.
31. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12:2654-66.
32. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990;8:1263-8.
33. Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996;14:1858-67.
34. Alberola V, Rosell R, Gonzalez-Larriba JL, Molina F, Ayala F, Garcia-Conde J, et al. Single agent Taxol, 3-hour infusion, in untreated advanced non-small-cell lung cancer. Ann Oncol 1995;6 (Suppl 3):S49-S52.
35. Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 1987;5:1232-9.
36. Kris MG, O'Connell JP, Gralla RJ, Wertheim MS, Parente RM, Schiff PB, et al. Phase I trial of taxol given as a 3-hour infusion every 21 days. Cancer Treat Rep 1986;70:605-7.
37. Donehower RC, Rowinsky EK, Grochow LB, Longnecker SM, Ettinger DS. Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep 1987;71:1171-7.
38. Grem JL, Tutsch KD, Simon KJ, Alberti DB, Willson JK, Tormey DC, et al. Phase I study of taxol administered as a short i.v. infusion daily for 5 days. Cancer Treat Rep 1987;71:1179-84.
39. Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, et al. Phase II trial of paclitaxel by 3-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 2003; 12:1133-7.
40. Cho H, Kanari M, Sano H, Tsuburaya A, Kobayashi O, Sairenji M, et al. A case of metastatic gastric cancer responding to weekly administration of paclitaxel as a second-line therapy. Jpn J Cancer Chemother 2003;30:129-32.
41. Suzuki T, Iwabuchi M, Matsuda Y, Imai G, Yokoyama H, Mochida A, et al. Treatment outcomes with paclitaxel for advanced gastric cancer patients previously treated with TS-1. Jpn J Cancer Chemother 2003;30:133-9.
42. Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC. Neurotoxicity of Taxol. J Natl Cancer Inst Monogr 1993;107-15.
43. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995;332:1004-14.
44. Yamamoto S, Tanaka Y, Ito T, Nakai S, Morimoto Y, Kitagawa T, et al. Weekly administration of paclitaxel with a short course of premedication for advanced or recurrent gastric cancer. Jpn J Cancer Chemother 2003;30:61-7.